AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate bio…
| Métrica | ACIU | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.4% | — |
| Operating Margin | -1940.0% | -34.4% | -1905.7% |
| Net Margin | -1971.7% | -32.5% | -1939.2% |
| FCF Margin | -1963.7% | -12.6% | -1951.1% |
| ROE | -156.9% | -39.2% | -117.8% |
| ROA | -45.7% | -30.9% | -14.7% |
| Current Ratio | 1.02 | 2.73 | -1.71 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -45.7% | — |
| ✗Flujo de caja operativo positivo | −CHF 69M | CHF 66M |
| ✗Rentabilidad sobre activos al alza | -45.7% | -22.0% |
| ✓Caja operativa/activos supera al ROA | -44.9% | ROA -45.7% |
| –Menos deuda a largo plazo | — | — |
| ✗Mejor liquidez (ratio corriente) | 1.02 | 1.71 |
| ✗Sin aumentar el nº de acciones | 101M | 100M |
| –Margen bruto al alza | — | — |
| ✗Rotación de activos al alza | 0.02 | 0.12 |
| Calidad del negocio | FY25 |
|---|---|
| ✗Margen FCF > 10 % | -1963.7% |
| ✗ROCE > 10 % | -116.4% |
| ✗Ventas > 5 %/año (3 años) | -3.2% |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 1604.7% |
AC Immune SA cotiza a 2.39 USD y tiene una capitalización bursátil de $238M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud